Bristol Myers Squibb and Pfizer announce plans to sell their
blockbuster blood thinner Eliquis directly to patients at a 40% discount, boosting their stocks. This aggressive move plays into a direct-to-consumer structure and is likely to reshape the market dynamics for anticoagulants. In other news, Bristol Myers Squibb has faced setback with their
anemia drug Reblozyl, which failed the Phase 3 trial, causing Morgan Stanley to maintain a sell rating on the company. Despite this, there is a strong institutional backing for the company with approximately 82% ownership. Investors closely watch as the company embarks on
advanced studies in Alzheimer's, solid tumors, and lung cancer, expecting potential game-changing breakthroughs. Cigna has sued the company alleging a monopoly over a blockbuster cancer drug. Moreover, the company expects to generate stable long-term income and impressing financial performance. Their commitment to innovation is further highlighted with the launch of a radiopharmaceutical manufacturing site in Indianapolis with RayzeBio.
Bristol-Myers Squibb News Analytics from Wed, 11 Dec 2024 08:00:00 GMT to Sat, 19 Jul 2025 23:24:42 GMT -
Rating 0
- Innovation 7
- Information 8
- Rumor 2
